Status:

RECRUITING

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Lead Sponsor:

Eli Lilly and Company

Conditions:

Obesity

Overweight

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include ab...

Eligibility Criteria

Inclusion

  • Have a body mass index (BMI) of:
  • ≥30 kilogram per square meter (kg/m2) OR
  • ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
  • Have at least one unsuccessful attempt to lose weight by dieting

Exclusion

  • Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening
  • Have a prior or planned surgical treatment for obesity
  • Have type 1 diabetes or type 2 diabetes
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • Have had within the past 90 days before screening
  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • hospitalization for unstable angina, or
  • hospitalization due to congestive heart failure
  • Have New York Heart Association Functional Classification Class IV congestive heart failure
  • Have a history of chronic or acute pancreatitis
  • Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Key Trial Info

Start Date :

November 17 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2027

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT07232719

Start Date

November 17 2025

End Date

July 1 2027

Last Update

January 6 2026

Active Locations (31)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (31 locations)

1

Artemis Institute for Clinical Research

Riverside, California, United States, 92503

2

JEM Research Institute

Atlantis, Florida, United States, 33462

3

Headlands Research Orlando

Orlando, Florida, United States, 32806

4

Care Access - Tamarac

Tamarac, Florida, United States, 33321

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | DecenTrialz